

Micromedex[®] POISINDEX[®]

Solution Brief

Designed to help clinicians quickly identify, treat and manage toxicological exposures

Highlights



Ingredient and toxic substance information on **428,000+** commercial products, chemicals, drugs, toxic plants and animals



Includes **current and discontinued** products



1,780+ detailed management/treatment protocols for exposure



Searchable by **2000+ slang drug terms**



Includes clinical effects, range of toxicity and more



Used for toxicology management **in all US** AAPCC-certified poison control centres



Used **by many** national and regional poison control centres around the world

Fast access to critical toxicology information with Micromedex POISINDEX.

- Access vital information with concise, essential toxicology data
- Save valuable time with at-a-glance product and substance identification
- Achieve accuracy with current evidence-based toxicology data—
- Help reduce errors even in uncommon or more complex situations
- Enhance patient care with toxicology data backed by trusted and respected editorial processes

Access to detailed information can help save lives

Many toxicology references provide high-level summary information on common exposures but fall short when it comes to uncommon or more complex situations. ● Micromedex POISINDEX helps clinicians identify ingredient and toxic substance information on 428,000+ commercial products, chemicals, drugs, toxic plants and animals. Data is delivered concisely to help provide fast access to critical lifesaving information.

Comprehensive Scope or complex cases

POISINDEX is the only system to link to additional databases, including:

- HAZARDEXTM for incidents such as spills, leaks, fires or explosives involving hazardous materials
- MEDITEXTM to assist in evaluating and treating acute exposures to industrial chemicals, reporting potential adverse health effects and treating chemical release exposures

1. Search for detailed toxicology data from our vast database

2. Identify product or substance by Name, Active Ingredient, Physical Description, Company, and AAPCC Code

3. Select a product from list to display summary in preview panel, links to related documents

4. Drill down to specific information, including clinical effects, treatment, abstracts and more

POISINDEX® is part of Micromedex®, a comprehensive suite of clinical products, providing critical information to healthcare organizations for more than 40 years.

Tox & Drug Product Lookup

Products and Substances | Martindale Global Drug | Company Contacts

Search for product or substance

Search by Name

- Drug product name
- Commercial/household product name or chemical
- Substance including plant and animal scientific or common name
- Slang terms/street names for drugs or substances

Search by Code

- AAPCC code - [Lookup Definitions](#)
- Micromedex product ID
- National Drug Code (NDC)
- Chemical Abstracts Service (CAS) number
- Drug Identification Number (DIN - Canada)
- Environmental Protection Agency (EPA) code
- Universal Product Code (UPC)
- Pest Control Product (PCP) code
- California Registry Number (CRN)
- Fertilizer Act

Tox & Drug Product / Substance Results

BENZENE

United States | Other Countries

View page: Preview List

Name	Active Ingredient	Physical Description	Company	AAPCC
1. BENZENE				192000
2. Benzene	benzene - 100%	Clear	Citgo Petroleum	192000
3. Benzene	benzene		Fisher Chemical	192000
4. Benzene	benzene - 99.80 TO 99.98% benzene, methyl-		Oxychem	192000

BENZENE

Micromedex Product ID 3311836 - 11/85 | AAPCC 192000 - Benzene

Toxicology Documentation

POISINDEX Managements

- BENZENE

MEDITEXT Medical Managements

Benzene

Quick Answers | In-Depth Answers | All Results

Overview

- Life Support
- Clinical Effects
- Laboratory/ Monitoring
- Treatment Overview
- Range Of Toxicity
- Substances Included/ Synonyms
- Therapeutic/ Toxic Class
- Specific Substances
- Available Forms/ Sources
- Clinical Effects
- Summary Of Exposure
- Heent
- Cardiovascular
- Respiratory
- Neurologic
- Gastrointestinal
- Hepatic
- Genitourinary
- Hematologic
- Dermatologic

Overview

Treatment Overview

View Full Document | Print

0.4.2) ORAL/PARENTERAL EXPOSURE

A) MANAGEMENT OF MILD TO MODERATE TOXICITY

1) Treatment is symptomatic and supportive. Correct any significant fluid and/or electrolyte abnormalities in patients with severe vomiting.

B) MANAGEMENT OF SEVERE TOXICITY

1) Treatment is symptomatic and supportive. Treat seizures with IV benzodiazepines; barbiturates or propofol may be needed if seizures persist or recur. Treat ventricular dysrhythmias using ACLS protocols. Endotracheal intubation and mechanical ventilation are likely to be necessary.

C) DECONTAMINATION

1) PREHOSPITAL: Prehospital GI decontamination is not recommended because of the risk of CNS depression or seizures and subsequent aspiration.

2) HOSPITAL: Consider insertion of a nasogastric tube to aspirate gastric contents if it can be performed soon (within an hour) after a very large ingestion. Protection of the airway should be ensured as there is a high risk of CNS depression and aspiration.

D) AIRWAY MANAGEMENT

1) Monitor for inadequate oxygenation and ventilation due to significant CNS depression and inadequate airway protection. Intubation and assisted ventilation may be necessary.

E) ANTIDOTE

1) There is no specific antidote for benzene exposure. The mainstay of therapy is aggressive supportive care.

F) SEIZURE

1) Administer IV benzodiazepines; barbiturates or propofol may be needed if seizures persist or recur.

Related Results

- Disease Toxicology
- Hazard Management Information
- Marindale Medical Management Information
- Product Lookup - Marindale Product Lookup - Tox & Drug

About Merative

Merative provides data and software for healthcare and government social services. With focused innovation and deep expertise, Merative works with providers, employers, health plans, governments, and life science companies to drive real progress. Merative helps clients orient information and insights around the people they serve to improve decision-making and performance. Merative, formerly IBM Watson Health, became a new standalone company as part of Francisco Partners in 2022. Learn more at merative.com.

© Copyright Merative US L.P. 2023
Merative
100 Phoenix Drive
Ann Arbor, Michigan 48108

Produced in the United States of America
December 2023

Merative, the Merative logo, Micromedex, and POSINDEX are trademarks of Merative in the United States, other countries or both. All other company or product names are registered trademarks or trademarks of their respective companies.

This document is current as of the initial date of publication and may be changed by Merative at any time. Not all offerings are available in every country in which Merative operates.

The information in this document is provided "as is" without any warranty, express or implied, including without any warranties of merchantability, fitness for a particular purpose and any warranty or condition of non-infringement. Merative products are warranted according to the terms and conditions of the agreements under which they are provided.

The client is responsible for ensuring compliance with all applicable laws and regulations applicable to it. Merative does not provide legal advice or represent or warrant that its services or products will ensure that the client is in compliance with any law or regulation. The performance data and client examples cited are presented for illustrative purposes only. Actual performance results may vary depending on the specific configurations and operating conditions. It is the user's responsibility to evaluate and verify the operation of any other products or programs with Merative product and programs.

Statement of Good Security Practices: IT system security involves protecting systems and information through prevention, detection and response to improper access from within and outside your enterprise. Improper access can result in information being altered, destroyed, misappropriated or misused or can result in damage to or misuse of your systems, including for use in attacks on others. No IT system or product should be considered completely secure and no single product, service or security measure can be completely effective in preventing improper use or access. Merative systems, products and services are designed to be part of a lawful, comprehensive security approach, which will necessarily involve additional operational procedures, and may require other systems, products or services to be most effective. Merative does not warrant that any systems, product or services are immune from, or will make your enterprise immune from, the malicious or illegal conduct of any party.